Abstract 375P
Background
Perturbations in key driver genes or recurrently somatic mutated genes, as well as altered signaling pathways underlying pancreatic cancer have been largely discovered with the help of massive parallel sequencing. However, to date, the relationships between somatic alterations occurrence and clinical features are still less understood in pancreatic cancer.
Methods
Using the genomic DNA from each sample, libraries were constructed by shearing genomic DNA and ligating Illumina paired-end adaptors first, then the constructed libraries were hybridized to Agilent Human All Exon Target Enrichment kit V1. The purified capture products were then amplified to make whole exome libraries. The qualified libraries were subjected to 150 base paired-end sequencing on the Illumina NovaSeq instrument. The Genome Analysis Toolkit (GATK) was used to call variants in the sequencing data. All the statistical analyses were performed using IBM SPSS Statistics version 23.0 software.
Results
In this study, a total of 54 pancreatic ductal adenocarcinoma patients were enrolled, and pancreatic tumour samples without matched normal tissues were subjected to whole-exome sequencing. Based on the high-confidence putative somatic genes identified from our tumour-only sequencing, the results revealed alterations in cancer progression- and metastatic-related signaling pathways (i.e., E-cadherin and CDC42 signaling pathways) were predominantly enriched in late-stage (stage III/IV) tumours. Moreover, mutant EHMT1, as well as KRT6C, were significantly associated with tumour stage, while mutant H3F3A, DPY19L2, ABCB5, and ASTN1 were all significantly associated with the degree of tumour differentiation.
Conclusions
Together, our data suggest the prevalence of association between somatic alteration at the genomic level and clinical features in pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract